Genmab

Results: 33



#Item
21Q&A GENMAB 4TH OF MARCH 2015 WITH JAN VAN DE WINKEL Q&A GENMAB 4TH OF MARCH 2015

Q&A GENMAB 4TH OF MARCH 2015 WITH JAN VAN DE WINKEL Q&A GENMAB 4TH OF MARCH 2015

Add to Reading List

Source URL: www.proinvestor.com

Language: English - Date: 2015-03-05 03:24:54
22If you cannot read this mail, click here.  December 16, 2010 As the year draws to an end May we take this opportunity to share with you our activities and

If you cannot read this mail, click here. December 16, 2010 As the year draws to an end May we take this opportunity to share with you our activities and

Add to Reading List

Source URL: www.amsterdameconomicboard.com

Language: English - Date: 2015-05-08 08:28:28
23If you cannot read this mail, click here.  August 18, 2009 Amsterdam BioMed News  Life Sciences Café - Sign up now!

If you cannot read this mail, click here. August 18, 2009 Amsterdam BioMed News Life Sciences Café - Sign up now!

Add to Reading List

Source URL: www.amsterdameconomicboard.com

Language: English - Date: 2015-05-08 08:28:20
24If you cannot read this mail, click here.  November 4, 2009 Amsterdam BioMed News  BioPortEurope kick off

If you cannot read this mail, click here. November 4, 2009 Amsterdam BioMed News BioPortEurope kick off

Add to Reading List

Source URL: www.amsterdameconomicboard.com

Language: English - Date: 2015-05-08 08:28:30
25DECEMBERBUILDING IN A NEW LIGHT

DECEMBERBUILDING IN A NEW LIGHT

Add to Reading List

Source URL: www.netpublikationer.dk

Language: English - Date: 2012-12-03 09:44:36
26Microsoft Word - Investment Press Release FINAL December 2010.doc

Microsoft Word - Investment Press Release FINAL December 2010.doc

Add to Reading List

Source URL: yuuwa.com.au

Language: English - Date: 2011-01-05 01:35:20
27GlycoVaxyn AG sells its shares to GSK GSK, who was already a minority shareholder in GlycoVaxyn, acquires the company and its biological conjugation platform which may help it to develop a new generation of prophylactic

GlycoVaxyn AG sells its shares to GSK GSK, who was already a minority shareholder in GlycoVaxyn, acquires the company and its biological conjugation platform which may help it to develop a new generation of prophylactic

Add to Reading List

Source URL: www.glycovaxyn.com

Language: English - Date: 2015-02-11 03:15:17
28JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of[removed]Therapeutic Area  Product Name

JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of[removed]Therapeutic Area Product Name

Add to Reading List

Source URL: files.shareholder.com

Language: English
29Microsoft Word - Arzerra Data Backgrounder_FINAL

Microsoft Word - Arzerra Data Backgrounder_FINAL

Add to Reading List

Source URL: us.gsk.com

Language: English
30Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange Aran F. Labrijna, Joyce I. Meestersa, Bart E. C. G. de Goeija, Ewald T. J. van den Bremera, Joost Neijssena, Muriel D. van Kampena, Kristin

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange Aran F. Labrijna, Joyce I. Meestersa, Bart E. C. G. de Goeija, Ewald T. J. van den Bremera, Joost Neijssena, Muriel D. van Kampena, Kristin

Add to Reading List

Source URL: www.pnas.org

Language: English - Date: 2013-03-11 11:44:53